EWA
RLMD icon

EverSource Wealth Advisors’s Relmada Therapeutics RLMD Stock Holding History

EverSource Wealth Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.2K Buy
+6,816
New +$47.6K ﹤0.01% 1809

Other funds holding RLMD

PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
AW
Apricus Wealth Beaufort, South Carolina $210M AUM 30.06% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
ACA
American Capital Advisory Ketchum, Idaho $275M AUM 22.21% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

EverSource Wealth Advisors's RLMD Position: Q2 2026 in Review

EverSource Wealth Advisors opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 6,816 shares worth $47.2K. The stake represents ﹤0.01% of the portfolio and ranks #1809 among its holdings.

9 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • EverSource Wealth Advisors held 6,816 shares of Relmada Therapeutics worth $47.2K as of Q2 2026.
  • Relmada Therapeutics was a new EverSource Wealth Advisors position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #1809 holding.
  • 9 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.